Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2025-05-08 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于举行2024年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding a 2024 annual online earnings presentation (业绩说明会) scheduled for May 16, 2025. It references the prior disclosure of the 2024 Annual Report and its summary but does not contain the report itself or detailed financial data. The document invites investors to participate and submit questions for the event. The length is short (876 characters), and the content is clearly an announcement of an event related to discussing financial results, not the results themselves or a transcript. Therefore, this fits the category of an Investor Presentation (IP) announcement or notice about the earnings call/presentation. Given the content and context, the best classification is Investor Presentation (IP).
2025-05-08 Chinese
关于持股5%以上股东减持计划的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding a shareholder holding more than 5% of the company's shares planning to reduce their holdings. It details the shareholder's name, current shareholding percentage, planned reduction amount, timing, and compliance with relevant securities laws and regulations. The document does not contain financial statements or performance data but focuses on the shareholder's intention to sell shares. This fits the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels crossing thresholds. The document length is about 2550 characters, consistent with a typical announcement rather than a full report. Therefore, the correct classification is MRQ with high confidence.
2025-05-06 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司2024年持续督导培训情况的报告
Regulatory Filings Classification · 95% confidence The document is titled as a report on the 2024 continuous supervision training conducted by CITIC Securities Co., Ltd. for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the training session's basic information, participants, content, and conclusions. The document is a formal report on a specific supervisory training activity rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements, voting results, or management changes. It is not an announcement of a report publication but the report itself. Therefore, it fits best under the category of Regulatory Filings (RNS) as it is a compliance-related report that does not fit other specific categories.
2025-04-30 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司2024年度跟踪报告
Management Reports Classification · 95% confidence The document is titled as a "2024年度跟踪报告" (2024 Annual Tracking Report) issued by 中信证券股份有限公司 (CITIC Securities Co., Ltd.) regarding 上海泓博智源医药股份有限公司 (Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd.). It details the sponsor's supervision work, company governance, compliance with regulatory requirements, and issues found during the year 2024. The content includes detailed descriptions of the sponsor's review of company disclosures, internal controls, fundraising supervision, governance, and regulatory sanctions received by the sponsor. The document is comprehensive and contains substantive information about the company's operations and compliance over the year, consistent with a management or sponsor's detailed report on company performance and oversight rather than a simple announcement or a financial statement. It is not a full annual report (10-K) of the company itself, nor is it an audit report or earnings release. It is a detailed management/sponsor report on the company's status and compliance during the year. Therefore, the best fitting category is Management Reports (MDA). The document length (7064 characters) supports it being a substantive report rather than a brief announcement or certification.
2025-04-30 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司2024年度持续督导定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2024年度持续督导定期现场检查报告" which translates to "2024 Annual Continuous Supervision On-site Inspection Report" by CITIC Securities for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It contains detailed findings from an on-site inspection covering governance, internal controls, information disclosure, protection of company interests, use of raised funds, performance, shareholder commitments, and other important matters. The document includes audit-like procedures, interviews, and verification of compliance with laws and regulations. It is not a full annual report (10-K), nor a simple announcement. It is a standalone audit or inspection report focusing on regulatory compliance and internal controls, consistent with an Audit Report / Information (AR) filing. The length and detail confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-30 Chinese
关于2025年第一季度计提信用减值损失及资产减值损失的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the provision for credit impairment losses and asset impairment losses for the first quarter of 2025. It details the amounts, reasons, accounting standards applied, and the impact on the company's financials. The document is relatively short (3424 characters) and focuses on a specific financial adjustment rather than presenting a full quarterly or annual financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). Instead, it is a regulatory announcement about impairment provisions, which fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure about financial adjustments without full report content.
2025-04-28 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.